The original STEP 1 trial established semaglutide 2.4mg as a breakthrough: 14.9% mean weight loss vs. 2.4% for placebo at 68 weeks. But 2.4mg was not the efficacy ceiling. Novo Nordisk's STEP-UP program tested whether higher doses — 3.6mg, 5.4mg, and 7.2mg — could push weight loss closer to bariatric surgery territory without unacceptable safety trade-offs.
STEP-UP 1 efficacy
STEP-UP 1 enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) without Type 2 diabetes. The trial tested semaglutide 7.2mg against 2.4mg and placebo, with a slow titration to the target dose over 20-24 weeks to minimize GI intolerance.
| Arm | Mean Weight Loss | ≥10% Weight Loss | ≥20% Weight Loss |
|---|---|---|---|
| Semaglutide 7.2mg | -20.7% | ~77% | ~54% |
| Semaglutide 2.4mg | ~-15% | ~62% | ~30% |
| Placebo | ~-2% | ~8% | ~3% |
The most clinically significant shift is in the ≥20% weight loss responder rate: roughly 54% of participants on 7.2mg lost at least 20% of their body weight, compared to ~30% on 2.4mg. This pushes semaglutide monotherapy into the response range previously achievable only with tirzepatide 15mg or bariatric surgery.
Dose-response curve
STEP-UP also tested intermediate doses (3.6mg, 5.4mg). The dose-response curve was not linear — the incremental benefit of each dose step diminished as the dose increased, suggesting the 7.2mg dose is approaching the pharmacological ceiling for semaglutide's weight loss effect as a single agent.
This has implications for clinical decision-making: patients who achieve satisfactory results on 2.4mg have less to gain from dose escalation than those who are partial responders. The 7.2mg dose is most valuable for patients who respond to semaglutide but haven't reached their treatment goals at the standard dose.
Safety and tolerability
GI adverse events increased with dose, as expected. Nausea was reported in approximately 40-45% of participants on 7.2mg during the titration phase, with most episodes classified as mild to moderate and resolving as treatment continued. The extended titration schedule (20-24 weeks to reach target dose, vs. 16 weeks for 2.4mg) was designed to mitigate the higher GI burden.
Discontinuation rates due to adverse events were higher for 7.2mg than 2.4mg — roughly 15-18% vs. 6-8%. This is the tolerability trade-off: better efficacy at the cost of more patients unable to tolerate the medication. The clinical question is whether the enhanced efficacy for those who tolerate 7.2mg justifies the higher drop-out rate across the treated population.
Semaglutide 7.2mg closes the efficacy gap between semaglutide monotherapy and tirzepatide 15mg, pushing mean weight loss above 20%. It does not match CagriSema's ~22-25% or tirzepatide's ~22% at 15mg, but it gives patients who respond well to semaglutide a higher-dose escalation path within the same molecule.
Regulatory timeline
Novo Nordisk has submitted a supplemental NDA for semaglutide 7.2mg. If approved, it would be marketed under the Wegovy brand as a higher-dose option for patients who need more aggressive weight management. The approval pathway is relatively straightforward — the active ingredient is already approved, and the submission is a dose extension rather than a new chemical entity. A PDUFA date in 2026-2027 is anticipated.
For patients, the practical impact is significant: instead of switching to a different molecule (tirzepatide) or a different mechanism (CagriSema) when 2.4mg plateaus, a dose increase within the same medication becomes an option. Compounding pharmacies already prepare semaglutide at custom doses — this approval would provide a brand-name alternative with standardized manufacturing and FDA oversight.